Drug intelligence / Profile preview

ganagliflozin

Development stage: Phase 4
Lead developer: Huisheng Biopharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Ganagliflozin is an oral small molecule drug that acts as a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It is developed by Jilin Huisheng Biopharmaceutical Co., Ltd. and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. It is indicated for the treatment of type 2 diabetes mellitus, and has also been studied for its effects on the progression of kidney disease in subjects with type 2 diabetes and chronic kidney disease. By inhibiting SGLT2, ganagliflozin reduces the reabsorption of filtered glucose in the kidneys, leading to increased urinary glucose excretion and a reduction in blood glucose levels.

Brand names: 惠优静

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on ganagliflozin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ganagliflozin.

Explore the full profile